An 8-Week, Double-Blind, Placebo-Controlled, Phase 3 Trial of Pregabalin (150-600 mg/Day) in the Adjunctive Treatment of Patients With Generalized Anxiety Disorder (GAD) Who Have Not Optimally Responded to Existing Therapies(GAD).

Trial Profile

An 8-Week, Double-Blind, Placebo-Controlled, Phase 3 Trial of Pregabalin (150-600 mg/Day) in the Adjunctive Treatment of Patients With Generalized Anxiety Disorder (GAD) Who Have Not Optimally Responded to Existing Therapies(GAD).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2012

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Feb 2012 Results published in the International Clinical Psychopharmacology.
    • 03 Feb 2010 Actual number of patients changed from 353 to 356 as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Additional trial locations identified as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top